Bertrand Tombal, Richard Berges

Slides:



Advertisements
Similar presentations
The PSA Era is not Over for Prostate Cancer
Advertisements

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 49, Issue 2, Pages (February 2006)
Reversible, Non-Barrier Male Contraception: Status and Prospects
Female Urinary Incontinence in the West of Turkey: Prevalence, Risk Factors and Impact on Quality of Life  Izzet Kocak, Pinar Okyay, Mehmet Dundar, Haluk.
Testosterone Therapy in Men With Prostate Cancer
Volume 49, Issue 2, Pages (February 2006)
Volume 49, Issue 2, Pages (February 2006)
Volume 54, Issue 4, Pages (October 2008)
Validity and Reliability of a Questionnaire for Evaluating Nocturia, Nocturnal Enuresis and Sleep-Interruptions in an Elderly Population  M.H. Bing, L.A.
Volume 51, Issue 1, Pages (January 2007)
Volume 53, Issue 5, Pages (May 2008)
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer  Olav Erich Yri, Trine Bjoro, Sophie D.
John P. Mulhall, Francesco Montorsi  European Urology 
Volume 63, Issue 4, Pages e53-e56 (April 2013)
Volume 52, Issue 1, Pages (July 2007)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 47, Issue 2, Pages (February 2005)
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 51, Issue 1, Pages (January 2007)
Elizabeth K. Bancroft, Rosalind A. Eeles
What is New in Hormone Therapy for Prostate Cancer in 2007?
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Prostate Cancer Detection: A View of the Future
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Volume 64, Issue 4, Pages (October 2013)
Volume 57, Issue 4, Pages e41-e42 (April 2010)
Volume 47, Issue 5, Pages (May 2005)
Volume 49, Issue 6, Pages (June 2006)
Prostate Cancer Epidemic in Sight?
James N. Armitage, Stuart O. Irving, Neil A. Burgess  European Urology 
Volume 48, Issue 4, Pages (October 2005)
The PSA Era is not Over for Prostate Cancer
Volume 70, Issue 1, Pages e27-e28 (July 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Treatment of Bacterial Urinary Tract Infections: Presence and Future
Paolo Puppo, Carlo Introini, Paolo Calvi, Angelo Naselli 
Richard C. Harkaway  European Urology Supplements 
Volume 47, Issue 1, Pages (January 2005)
The Economic Costs of Overactive Bladder in Germany
Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl  European Urology 
Volume 50, Issue 5, Pages (November 2006)
Volume 46, Issue 5, Pages (November 2004)
Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
The Importance of Testosterone Control in Prostate Cancer
Testicular Cancer Variations in Time and Space in Europe
Optimal Testosterone Control and Eligard®
Neal Shore  European Urology Supplements 
European Urology is “Your” Journal
New Trends in Managing the Prostate Cancer Patient
The Start-Up of the Platinum Journal: A Fascinating Challenge
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer  P. Mongiat-Artus, P. Teillac 
Richard Berges  European Urology Supplements 
Economic Burden of Bladder Cancer Across the European Union
Volume 51, Issue 2, (February 2007)
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Hormone Therapy: Improving Therapy Decisions and Monitoring
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?  B. Tombal  European Urology.
Presentation transcript:

Bertrand Tombal, Richard Berges Corrigendum to: “How Good do Current LHRH Agonists Control Testosterone? Can this be Improved with Eligard®?” [Eur Urol Suppl 4/8 (2005) 30–36]  Bertrand Tombal, Richard Berges  European Urology  Volume 49, Issue 5, (May 2006) DOI: 10.1016/j.eururo.2006.03.032 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 About 2–17% of patients fail to achieve a testosterone level of 50ng/dL [13–17]. European Urology 2006 49, DOI: (10.1016/j.eururo.2006.03.032) Copyright © 2006 Elsevier B.V. Terms and Conditions